Fmr LLC Buys 680,000 Shares of Minerva Neurosciences, Inc (NERV)
Fmr LLC grew its stake in Minerva Neurosciences, Inc (NASDAQ:NERV) by 13.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,660,794 shares of the biopharmaceutical company’s stock after acquiring an additional 680,000 shares during the quarter. Fmr LLC owned about 15.42% of Minerva Neurosciences worth $50,098,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Nationwide Fund Advisors lifted its position in shares of Minerva Neurosciences by 14.2% in the second quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 1,616 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Minerva Neurosciences in the first quarter valued at $110,000. Russell Investments Group Ltd. lifted its position in shares of Minerva Neurosciences by 54.6% in the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 5,579 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Minerva Neurosciences in the second quarter valued at $159,000. Finally, Alpine Woods Capital Investors LLC lifted its position in shares of Minerva Neurosciences by 100.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 20,000 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 69.29% of the company’s stock.
Minerva Neurosciences, Inc (NASDAQ:NERV) opened at 7.15 on Tuesday. Minerva Neurosciences, Inc has a 1-year low of $5.55 and a 1-year high of $14.15. The firm’s market capitalization is $303.94 million. The company has a 50-day moving average price of $7.12 and a 200 day moving average price of $7.64.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.07. During the same period last year, the firm posted ($0.18) earnings per share. Equities analysts anticipate that Minerva Neurosciences, Inc will post ($0.90) earnings per share for the current year.
Several research firms recently commented on NERV. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Citigroup Inc. began coverage on Minerva Neurosciences in a research note on Friday, September 1st. They issued a “buy” rating and a $11.00 target price for the company. Finally, BidaskClub lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.94.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.